Xoma Corp (XOMA) Gets a Hold Rating from Cowen & Co.

By Carrie Williams

Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Xoma Corp (XOMAResearch Report) today. The company’s shares closed yesterday at $13.88, close to its 52-week low of $11.88.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.9% and a 51.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Allogene Therapeutics Inc.

Currently, the analyst consensus on Xoma Corp is a Moderate Buy with an average price target of $36.

See today’s analyst top recommended stocks >>

Based on Xoma Corp’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $4.58 million. In comparison, last year the company had a net profit of $16.04 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from unique platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Berkeley, CA.